anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a chlorfenapyr composition for preventing and controlling crossocosmia sericariae. The chlorfenapyr composition comprises chlorfenapyr agent powder, an assistant and water. The invention discloses a preparation method of the chlorfenapyr composition for preventing and controlling crossocosmia sericariae. A suspending agent stoste containing chlorfenapyr is prepared from the chlorfenapyr powder after a certain ratio of assistant is added. The invention also discloses an application method of the chlorfenapyr composition. A solution containing 0.1-0.03% of chlorfenapyr effective component is prepared from the prepared suspending agent stoste according to the silkworm breeding amount in a manner of diluting by water. The solution is evenly sprayed on the surface of each folium mori, then fed to the silkworms after being evenly mixed, and respectively added to the silkworms at the fifth stage. The composition is simple in preparation step, and the application method is easy to operate, so that the prevention, control and application are convenient, easy and time-saving, the chlorfenapyr composition is small in dosage and is not frequent in usage count, prevention and treatment are just required at the fifth stage of silk and cocoon cultivation of the silkworms, and contribution to research and development of a novel drug for preventing and treating exorista sorbillans is made.
Chronic obstructive pulmonary disease (COPD) is a common but underdiagnosed lung condition that is frequently managed inappropriately. It impacts poorest communities most, where health inequalities are greatest. New acute symptoms of breathlessness, cough, sputum production and wheeze should prompt clinical suspicion of underlying COPD in someone who is a current or ex-smoker (or has exposure to other risk factors) and be followed by referral for quality-assured spirometry once recovered. Management of COPD exacerbations in primary care includes use of short-acting bronchodilators if mild, and antibiotics and a short course of oral prednisolone if moderate/severe. Hospital at home schemes are safe and effective and should be considered for some patients exacerbating in the community; these are increasingly supported by remote monitoring ('virtual wards'). New or worsening hypoxia is an indication for hospital admission and therefore oxygen saturation monitoring is an important part of exacerbation management; clinicians should be aware of patient safety alerts around use of pulse oximeters. Exacerbations drive poor health status and lung function decline and therefore asking about exacerbation frequency at planned reviews and taking action to reduce these is an important part of long-term COPD care. An exacerbation is an opportunity to ensure that fundamentals of good care are addressed. Patients should be supported to understand and act on exacerbations through a supported self-management plan; prompt treatment is beneficial but should be balanced by careful antibiotic and corticosteroid stewardship. COPD rescue packs on repeat prescription are not recommended.
Approximately 15 million babies are born preterm (<37 weeks of completed gestation) worldwide annually. Although neonatal and perinatal medicine have contributed to the increased survival rate of preterm newborn infants, premature infants are at increased risk of mortality in the first years of life. Infants born preterm are at four times the risk of Sudden Infant Death Syndrome (SIDS) compared to infants born at term. SIDS is believed to be multifactorial in origin. The Triple Risk hypothesis has been proposed to explain this. The model suggests that when a vulnerable infant, such as one born preterm, is at a critical but unstable developmental period in homeostatic control, death may occur if exposed to an exogenous stressor, such as being placed prone for sleep. The highest risk period is at ages 2-4 months, with 90 % of deaths occurring before 6 months. The final pathway to SIDS is widely believed to involve some combination of immature cardiorespiratory control and a failure of arousal from sleep. This review will focus on the physiological factors which increase the risk for SIDS in preterm infants and how these factors may be identified and potentially lead to effective preventative strategies.
The field of this invention is measuring efficacy of cancer treatments. In particular the fields of this invention include studies of drug efficacy, use of animals in medical studies, use of animals in vivariums, and use of rodents, particularly mice. Cells from a neoplasm are injected into subject test animals in a specific organ or a specific location of a specific organ, such as the brain. Some of the subject animals receive therapeutic treatments. The behavior of the animals is observed using fully automatic, continuous monitoring using per-cage sensors, where behavior recording is free of human, manual actions. Observed behavior is consistent with healthy or unhealthy behaviors specific to the injection site. Both positive and negative baseline behaviors are collected, typically using the same system or method. Efficacy is measured by comparing treatments under test to both the positive and negative baselines, using multi-dimensional analysis.
Embodiments of the inventive subject matter include systems, methods and computer program products for navigating clinical documents associated with health care visits. Clinical documents for a patient are obtained. The clinical documents are documents associated with a plurality of care visits by the patient. The clinical documents are analyzed in order to determine importance ratings for the care visits. A timeline is displayed where the timeline includes graphical elements representing the care visits. The graphical elements are displayed on the timeline in accordance with a time of the care visit and the importance rating of the care visit.
Safe oral feeding is a challenge for infants born with complex congenital heart disease (CHD). These infants are likely to require tube-assisted feeding at the initiation of enteral feeding and struggle to transition to full oral feeding. Infant post-surgery recovery includes a safe transition to oral feeding without respiratory risk. Neoneur Feeding System, consists of a novel hand-held, mobile phone application, and a cloud based computation, which innovatively measures patterns of oral cavity pressure synchronized with respiration, providing a quantitative assessment of feeding patterns. Yet there has been no quantitative means of measuring this recovery process. The concept of post-surgical recovery model is not new. The adult literature is replete with physiologic and behavioral indicators of recovery. More recently Roy and colleagues introduced a recovery model for post-surgical CHD children to adults using a component metrics of physiologic parameters. We are proposing to develop an infant specific recovery model using feeding patterns using data generated by the Neoneur device. The model, using the lens of behavioral organization, will include feeding measurements from initiation of oral feeding to discharge.

This study will evaluate the association between feeding recovery and clinical assessment of infant behaviors as measured in a brief survey to assess irritability, ability to be soothed, alertness, non-nutritive sucking, and muscle tone. Forty infants will be recruited from the PCICU-CSD at MUSC to capture thirty usable infant sets of Neoneur data from the PCICU-CSD at MUSC. This data will be assessed using the Neoneur Feeding System to create a model of feeding recovery.
The present invention provides a creatine containing caramel composition which increases the efficiency of a creatine dose. Particularly, micronized creatine is uniformly dispersed in a caramel composition having an insulin response enhancing amount of an invert sugar. The average particle size of micronized creatine is smaller than about 200 mesh. Such a size enables the gastrointestinal tract to absorb a greater percentage of the creatine than normally sized creatine. Additionally, the reduced particle size works in conjunction with the insulin response provoked by the sugar to allow the greater absorption of creatine by the muscle cells. Additionally, the present invention presents a method of reducing or eliminating a bitter taste caused by micronized creatine. Particularly, the micronized creatine is uniformly dispersed in a caramel composition containing a sufficient amount of invert sugar to reduce or eliminate any bitter taste or after taste.
All patients received treatment according to their group: For group I, received threaded tapered screw appliance therapy . The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printer was loaded with material of 3D-printed denture base. The appliance was printed.

For group II received low-level laser therapy, the laser type was of diode laser.The laser apparatus consisted of a hand piece with two attachments: either a plastic tip was attached to the same hand piece to transfer laser energy intro-orally when it was used to irradiate the lateral pterygoid muscle, or a specially designed optic prism was attached to the tip of the prism for extraoral application on extra oral muscles. All patients in this group received low level laser therapy twice times a week for 6 weeks totaling 12 sessions. In each session, the laser beam was applied in a three phases treatment protocol as follows: (a) The insertion of the lateral pterygoid muscle into the condylar neck and disc was treated in the first phase by applying a laser beam 1 cm anterior to the condyle below the zygomatic arch. (b) Tender spots in the masseter and temporalis muscles that were found during the initial assessment were exposed to radiation during the second phase. (c) The lateral pterygoid muscle origin was exposed to radiation in the third phase, which was performed with the mouth slightly open and intro-orally posterior to the final molar. During each phase, the laser was operated for two minutes per area at a wavelength of 810 nm and a peak output of 500 mW. It was applied continuously, a little distance away from the tissues. The laser probe was positioned perpendicular to the target area. Prior to usage, the laser was calibrated. Protective glasses were worn by the clinician and the patients. For group III, received low-level laser therapy in addition to threaded tapered screw appliance therapy as mentioned previously in group I and group II. Concurrent with the initial low level laser therapy session, screw tapered appliance was used for the first time.

Throughout the trial, no medication was administered to any of the groups. The patients were not allowed to use any painkillers or analgesics.
After having been informed about the study and the potential risks, all participants giving written informed consent will undergo screening to determine eligibility for study entry (inclusion criteria). At baseline (t0), a fasting blood sample will be taken by venipuncture from the participants, and they will be randomly assigned in a double-blind manner (investigator and participant) to one of the intervention groups, i.e. meal including the consumption of the functional yogurt (yogurt enriched with probiotics and polyphenols) or consumption of yogurt enriched with probiotics or consumption of placebo yogurt. The participants have to finish their meals within 15 minutes (t1) and after the meal, blood sampling will be repeated for the times, t2 = 30 min, t3 = 90 min, t4 = 180min. After a washout period of 7 days, the participants will consume the functional yogurt, or the yogurt enriched with probiotics, or the placebo yogurt, in a cross-over design, and the blood sampling will be carried out as described above. Finally, after a washout period of 7 days, the participants will consume the functional yogurt, or the yogurt enriched with probiotics or the placebo yogurt in a cross-over design, and the blood sampling will be carried out as described above. Throughout the interventional period participants' dietary intake, anthropometrical data, medical history, and dietary habits will be monitored.
All groups will perform the same procedures twice weekly. Volunteers will be comfortable with the affected foot exposed. The diabetic foot ulcers (DFU) will be cleaned using saline solution and gauze, then the ulcer temperature will be checked using the digital infrared thermometer. Diabetic wounds will be measured and photographed at baseline and every 10 visits until the study is completed, the images will be analyzed using the ImageJ program for follow-up throughout the intervention. The DFU will be ranked according to the Wagner Scale. Afterwards the volunteers will receive LLLT application and conventional treatment in the form of Helianthus Annuus oil dressing. Both therapist and participant will be instructed on precautions to be observed when using LLLT. Goggles will be provided prior to administration. The lower cylinder of the LASER probe will be placed perpendicular to the DFU, the floor and edges of the ulcer will be irradiated using punctual and scanning techniques, respectively. Once a week blood glucose levels will be obtained for patient screening. All data will be recorded until the end of the visits in a control form prepared.
Chemotherapy is a widely used treatment for a variety of solid and hematological malignancies. Despite its success in improving the survival rate of cancer patients, chemotherapy causes significant toxicity to multiple organs, including the skeleton, but the underlying mechanisms have yet to be elucidated. Using tumor-free mouse models, which are commonly used to assess direct off-target effects of anti-neoplastic therapies, we found that doxorubicin caused massive bone loss in wild-type mice, a phenotype associated with increased number of osteoclasts, leukopenia, elevated serum levels of danger-associated molecular patterns (DAMPs; e.g. cell-free DNA and ATP) and cytokines (e.g. IL-1β and IL-18). Accordingly, doxorubicin activated the absent in melanoma (AIM2) and NLR family pyrin domain containing 3 (NLRP3) inflammasomes in macrophages and neutrophils, causing inflammatory cell death pyroptosis and NETosis, which correlated with its leukopenic effects. Moreover, the effects of this chemotherapeutic agent on cytokine secretion, cell demise, and bone loss were attenuated to various extent in conditions of AIM2 and/or NLRP3 insufficiency. Thus, we found that inflammasomes are key players in bone loss caused by doxorubicin, a finding that may inspire the development of a tailored adjuvant therapy that preserves the quality of this tissue in patients treated with this class of drugs.
Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
OBJECTIVE: The study aims to assess regional and total bone metabolic activity in patients with chronic kidney disease using Na[18F]F PET and correlation between semi-quantitative indices and blood parameters.
METHODS: Seventy-two subjects (mean age 61.8 ± 13.8 years) were included. Of these 24/72 patients had end-stage renal disease (ESRD) (GFR < 15 mL/min/1.73 m2), 38/72 had chronic kidney disease (CKD) (GFR between 60 and 15 mL/min/1.73 m2), and 10/72 were controls with normal renal function. All subjects underwent Na[18F]F PET-CT with a dose activity of 0.06 mCi/Kg. Regional and total skeletal metabolism were assessed with mean SUVs in a skeletal volume of interest (VOI), bone to soft tissue index (B/S), global SUV mean (GSUV mean) of the whole bone, and uptake in the femoral neck.
RESULTS: Statistically significant differences were observed in a number of 18F-NaF metrics like femoral neck metabolism in CKD and ERSD groups in comparison to control in right (P = 0.003) and left femur (P = 0.006), bone to soft tissue index in the femur (P = 0.016) and GSUV5 (P = 0.006). There is also a significant difference in SUV mean in lumbar vertebrae (L1-L4) among CKD, ESRD, and controls. There was a moderate correlation between 18F-NaF PET scan uptake and blood parameters such as ALP and PTH. Na[18F]F uptake parameters were significantly different in low versus high bone turnover state.
CONCLUSIONS: The assessment of total skeleton and regional metabolism and bone turnover in CKD patients is feasible with Na[18F]F PET. Na[18F]F can help to detect early changes in bone metabolism and assess the progression of bone disease in this complex condition. Quantification with Na[18F]F PET might provide better assessment of the bone turnover. The difference in Na[18F]F uptake in CKD compared to controls is likely related to a change in bone turnover which, however, requires further validation.
The present invention provides low molecular weight imitated stichopus japonicus selenka glycosaminoglycans, a preparation method, and applications thereof. Structural formula of the low molecular weight imitated stichopus japonicus selenka glycosaminoglycan is as follows: the skeletal structure is repetition structures of -4GlcUA beta 1-3GalNAc beta 1-disaccharide, and the O-4/6 site of acetyl aminogalactose is sulfated. Every disaccharide unit has a fucose branched chain, the fucose is 2, 4-bis substituted by sulphate groups, the possible connection sites are O-3 site (R) of glucuronate, or O-4 site (R1) or O-6 site (R2) of acetyl aminogalactose. M=7-12. The low molecular weight imitated stichopus japonicus selenka glycosaminoglycans with weight average molecular weight (Mw) in the range of 7000 to 12,000 accounts for 95%. The purity is more than 98%. The low molecular weight imitated stichopus japonicus selenka glycosaminoglycans can be applied to anticoagulation and antithrombotic therapy, can reduce bleeding risk at the same time, and provides method support for the development of holothurian glycosaminoglycan products with similar structures.
Group 2 receives three decision aids. This group does not receive any feedback from the SPI.
The material can be appled for primary filling in the treatment of caries in particular deep ones. It remineralizes the dentine with a composition very close to the original one having high microhardness. It can also be applied as an ingredient of a promedicament for teeth such as tooth pastes, elixirs, cotton threads and powders. The material includes a mixture of cation and anion exchange resins, charged with Ca2+, F- and PO43- ions, in appr. mole ratio of 2:1:1. Material where the resins also have a charge of Zn2+ ions is preferred in presence of quantities less than 1%, better closer to 0.2%, of the dry weight of the resin. Resins are suitable the base of which is of laterally cross linked polystyrene with 2 to 14% divinylbenzene. 15 claims
Diaphragm training for dysphagia in elderly nursing home residents involves exercises and techniques aimed at strengthening the diaphragm muscle to improve swallowing function. Dysphagia, or difficulty swallowing, is common among older adults and can lead to complications such as malnutrition, dehydration, and aspiration pneumonia. Diaphragm training may include breathing exercises, postural adjustments, and swallowing maneuvers designed to enhance coordination and strength in the muscles involved in the swallowing process. By targeting the diaphragm, which plays a crucial role in breathing and swallowing coordination, this training approach aims to alleviate dysphagia symptoms and improve overall swallowing function in elderly nursing home residents, thus enhancing their quality of life and reducing the risk of associated health complications.

The goal of this clinical trial is to explore the Diaphragm Training on swallowing function in Elderly Nursing Home Residents (≥60 year old) with swallowing disorders. It primarily aims to address: the effects of Diaphragm Training on swallowing function and quality of life in Elderly Nursing Home Residents. All participants are divided into 2 groups. The intervention group is required to undergo a continuous three-week (21 days) Diaphragm Training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 30 minutes each.
EDP1815 or placebo in capsule A, dosed for 60 days. Randomization is 2:1 active:placebo.
518,788. Hormones. BRITISH DRUG HOUSES, Ltd., and MARSHALL, P. G. Sept. 3, 1938, No. 25841. [Class 81 (i)] Gonad stimulating hormone is obtained from pregnancy urine by adsorbing the hormone on benzoic or cinnamic acid formed in situ in the urine by addition of an alkali salt of the acid followed by addition of just sufficient hydrochloric acid, separating the precipitate and removing the hormone therefrom by dissolving the acid by a solvent (e.g. acetone) and after purification of the, hormone, rapidly concentrating its solution by evaporation in vacuo at a temperature not above 25‹C. The purification of the hormone after removal of the adsorbent and prior to concentration may be effected by solution in alkali, e.g. dilute ammonia, precipitation with ammonium sulphate, removal and solution of the precipitate in water and dialyzation of the solution to remove ammonium sulphate. The evaporation may be effected at temperatures below the freezing point of the solution and phosphorus pentoxide or anhydrous magnesium perchlorate may be used to assist the removal of last traces of water. Specification 406,531 is referred to.
In the control (sham-RIPC) group the cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the the control group.
The treatment of helicobacter pylori is very important. The routine treatment is quadruple therapy. In recent years, double therapy has appeared and the curative effect is fair. However, antacid generally uses proton pump inhibitor. The proton pump inhibitor needs double dose to achieve good antacid curative effect. The effect of vonoprazan used for inhibiting gastric acid is better than proton pump inhibitor. At present, many studies use vonoprazan instead of common proton pump inhibitor, but almost all use double dose of vonoprazan. In the previous study, we found that the effect of double dose of proton pump inhibitor can be achieved with 20mg QD of vonoprazan. Therefore, in this study, 20mg QD of vonoprazan was used to replace the double dose of proton pump inhibitor to observe the antibacterial effect of vonoprazan on Helicobacter pylori.
Participants in this arm will be offered the intervention once the LTP+ arm have completed their outcome assessment. For example, in each Union Council (UC) once the LTP+ arm has completed the intervention and 4th month outcome assessment the wait-list control group in the same UC will be offered the intervention.
Participants who will complete Part-1 will be randomized to receive oral Paliperidone Palmitate (PP) treatment. Participants will receive 5 doses of PP1M (paliperidone palmitate once-monthly injection). First dose at a starting dose of 234 mg on Day 1 and thereafter second dose in second week and then, every month up to Day 92. Participants will be subsequently switched to PP3M (paliperidone palmitate three-monthly injection) following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.